Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences

Qianhong Li, Yiru Guo, Wei Tan, Adam B. Stein, Buddhadeb Dawn, Wen Jian Wu, Xiaoping Zhu, Xiaoqin Lu, Xiaoming Xu, Tariq Siddiqui, Sumit Tiwari, Roberto Bolli

Research output: Contribution to journalArticle

Abstract

Previous studies have shown that gene therapy with inducible nitric oxide synthase (iNOS) protects against myocardial infarction at 3 days after gene transfer. However, the long-term effects of iNOS gene therapy on myocardial ischemic injury and cardiac function are unknown. To address this issue, we used a recombinant adenovirus 5 (Ad5) vector (Av3) with deletions of the E1, E2a, and E3 regions, which enables long-lasting recombinant gene expression for at least 2 mo due to lack of inflammation. Mice received intramyocardial injections in the left ventricular (LV) anterior wall of Av3/LacZ (LacZ group) or Av3/iNOS (iNOS group); 1 or 2 mo later, they were subjected to myocardial infarction (30-min coronary occlusion followed by 4 h of reperfusion). Cardiac iNOS gene expression was confirmed by immunoblotting and activity assays at 1 and 2 mo after gene transfer. In the iNOS group, infarct size (percentage of risk region) was significantly reduced (P <0.05) both at 1 mo (24.2 ± 3.4%, n = 6, vs. 48.0 ± 3.6%, n = 8, in the LacZ group) and at 2 mo (23.4 ± 3.1%, n = 8, vs. 36.6 ± 2.4%, n = 7). The infarct-sparing effects of iNOS gene therapy were as powerful as those observed 24 h after ischemic preconditioning (23.1 ± 3.4%, n = 10). iNOS gene transfer had no effect on LV function or dimensions up to 8 wk later (echocardiography). These data demonstrate that iNOS gene therapy mediated by the Av3 vector affords long-term (2 mo) cardioprotection without inflammation or adverse functional consequences, a finding that provides a rationale for further preclinical testing of this therapy.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume290
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Nitric Oxide Synthase Type II
Genetic Therapy
Myocardial Infarction
Genes
Inflammation
Gene Expression
Ischemic Preconditioning
Coronary Occlusion
Left Ventricular Function
Immunoblotting
Adenoviridae
Reperfusion
Echocardiography
Injections
Wounds and Injuries

Keywords

  • Cardiac function
  • Mouse
  • Nitric oxide synthase

ASJC Scopus subject areas

  • Physiology

Cite this

Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. / Li, Qianhong; Guo, Yiru; Tan, Wei; Stein, Adam B.; Dawn, Buddhadeb; Wu, Wen Jian; Zhu, Xiaoping; Lu, Xiaoqin; Xu, Xiaoming; Siddiqui, Tariq; Tiwari, Sumit; Bolli, Roberto.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 290, No. 2, 02.2006.

Research output: Contribution to journalArticle

Li, Qianhong ; Guo, Yiru ; Tan, Wei ; Stein, Adam B. ; Dawn, Buddhadeb ; Wu, Wen Jian ; Zhu, Xiaoping ; Lu, Xiaoqin ; Xu, Xiaoming ; Siddiqui, Tariq ; Tiwari, Sumit ; Bolli, Roberto. / Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. In: American Journal of Physiology - Heart and Circulatory Physiology. 2006 ; Vol. 290, No. 2.
@article{293e103795b64e40b70bfd52f48478ee,
title = "Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences",
abstract = "Previous studies have shown that gene therapy with inducible nitric oxide synthase (iNOS) protects against myocardial infarction at 3 days after gene transfer. However, the long-term effects of iNOS gene therapy on myocardial ischemic injury and cardiac function are unknown. To address this issue, we used a recombinant adenovirus 5 (Ad5) vector (Av3) with deletions of the E1, E2a, and E3 regions, which enables long-lasting recombinant gene expression for at least 2 mo due to lack of inflammation. Mice received intramyocardial injections in the left ventricular (LV) anterior wall of Av3/LacZ (LacZ group) or Av3/iNOS (iNOS group); 1 or 2 mo later, they were subjected to myocardial infarction (30-min coronary occlusion followed by 4 h of reperfusion). Cardiac iNOS gene expression was confirmed by immunoblotting and activity assays at 1 and 2 mo after gene transfer. In the iNOS group, infarct size (percentage of risk region) was significantly reduced (P <0.05) both at 1 mo (24.2 ± 3.4{\%}, n = 6, vs. 48.0 ± 3.6{\%}, n = 8, in the LacZ group) and at 2 mo (23.4 ± 3.1{\%}, n = 8, vs. 36.6 ± 2.4{\%}, n = 7). The infarct-sparing effects of iNOS gene therapy were as powerful as those observed 24 h after ischemic preconditioning (23.1 ± 3.4{\%}, n = 10). iNOS gene transfer had no effect on LV function or dimensions up to 8 wk later (echocardiography). These data demonstrate that iNOS gene therapy mediated by the Av3 vector affords long-term (2 mo) cardioprotection without inflammation or adverse functional consequences, a finding that provides a rationale for further preclinical testing of this therapy.",
keywords = "Cardiac function, Mouse, Nitric oxide synthase",
author = "Qianhong Li and Yiru Guo and Wei Tan and Stein, {Adam B.} and Buddhadeb Dawn and Wu, {Wen Jian} and Xiaoping Zhu and Xiaoqin Lu and Xiaoming Xu and Tariq Siddiqui and Sumit Tiwari and Roberto Bolli",
year = "2006",
month = "2",
doi = "10.1152/ajpheart.00855.2005",
language = "English (US)",
volume = "290",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences

AU - Li, Qianhong

AU - Guo, Yiru

AU - Tan, Wei

AU - Stein, Adam B.

AU - Dawn, Buddhadeb

AU - Wu, Wen Jian

AU - Zhu, Xiaoping

AU - Lu, Xiaoqin

AU - Xu, Xiaoming

AU - Siddiqui, Tariq

AU - Tiwari, Sumit

AU - Bolli, Roberto

PY - 2006/2

Y1 - 2006/2

N2 - Previous studies have shown that gene therapy with inducible nitric oxide synthase (iNOS) protects against myocardial infarction at 3 days after gene transfer. However, the long-term effects of iNOS gene therapy on myocardial ischemic injury and cardiac function are unknown. To address this issue, we used a recombinant adenovirus 5 (Ad5) vector (Av3) with deletions of the E1, E2a, and E3 regions, which enables long-lasting recombinant gene expression for at least 2 mo due to lack of inflammation. Mice received intramyocardial injections in the left ventricular (LV) anterior wall of Av3/LacZ (LacZ group) or Av3/iNOS (iNOS group); 1 or 2 mo later, they were subjected to myocardial infarction (30-min coronary occlusion followed by 4 h of reperfusion). Cardiac iNOS gene expression was confirmed by immunoblotting and activity assays at 1 and 2 mo after gene transfer. In the iNOS group, infarct size (percentage of risk region) was significantly reduced (P <0.05) both at 1 mo (24.2 ± 3.4%, n = 6, vs. 48.0 ± 3.6%, n = 8, in the LacZ group) and at 2 mo (23.4 ± 3.1%, n = 8, vs. 36.6 ± 2.4%, n = 7). The infarct-sparing effects of iNOS gene therapy were as powerful as those observed 24 h after ischemic preconditioning (23.1 ± 3.4%, n = 10). iNOS gene transfer had no effect on LV function or dimensions up to 8 wk later (echocardiography). These data demonstrate that iNOS gene therapy mediated by the Av3 vector affords long-term (2 mo) cardioprotection without inflammation or adverse functional consequences, a finding that provides a rationale for further preclinical testing of this therapy.

AB - Previous studies have shown that gene therapy with inducible nitric oxide synthase (iNOS) protects against myocardial infarction at 3 days after gene transfer. However, the long-term effects of iNOS gene therapy on myocardial ischemic injury and cardiac function are unknown. To address this issue, we used a recombinant adenovirus 5 (Ad5) vector (Av3) with deletions of the E1, E2a, and E3 regions, which enables long-lasting recombinant gene expression for at least 2 mo due to lack of inflammation. Mice received intramyocardial injections in the left ventricular (LV) anterior wall of Av3/LacZ (LacZ group) or Av3/iNOS (iNOS group); 1 or 2 mo later, they were subjected to myocardial infarction (30-min coronary occlusion followed by 4 h of reperfusion). Cardiac iNOS gene expression was confirmed by immunoblotting and activity assays at 1 and 2 mo after gene transfer. In the iNOS group, infarct size (percentage of risk region) was significantly reduced (P <0.05) both at 1 mo (24.2 ± 3.4%, n = 6, vs. 48.0 ± 3.6%, n = 8, in the LacZ group) and at 2 mo (23.4 ± 3.1%, n = 8, vs. 36.6 ± 2.4%, n = 7). The infarct-sparing effects of iNOS gene therapy were as powerful as those observed 24 h after ischemic preconditioning (23.1 ± 3.4%, n = 10). iNOS gene transfer had no effect on LV function or dimensions up to 8 wk later (echocardiography). These data demonstrate that iNOS gene therapy mediated by the Av3 vector affords long-term (2 mo) cardioprotection without inflammation or adverse functional consequences, a finding that provides a rationale for further preclinical testing of this therapy.

KW - Cardiac function

KW - Mouse

KW - Nitric oxide synthase

UR - http://www.scopus.com/inward/record.url?scp=33644871719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644871719&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00855.2005

DO - 10.1152/ajpheart.00855.2005

M3 - Article

VL - 290

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 2

ER -